𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Ethnicity and nonalcoholic fatty liver disease

✍ Scribed by Kiran Bambha; Patricia Belt; Maria Abraham; Laura A. Wilson; Mark Pabst; Linda Ferrell; Aynur Unalp-Arida; Nathan Bass; for the Nonalcoholic Steatohepatitis Clinical Research Network Research Group


Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
825 KB
Volume
55
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder in the United States; however, few data are available about racial and ethnic variation. We investigated relationships between ethnicity, NAFLD severity, metabolic derangements, and sociodemographic characteristics in a well-characterized cohort of adults with biopsy-proven NAFLD. Data were analyzed from 1,026 adults (!18 years) in the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) from 2004 to 2008, for whom liver histology data were available within 6 months of enrollment. Associations between ethnicity (i.e., Latino versus non-Latino white) and NAFLD severity (i.e., NASH versus non-NASH histology and mild versus advanced fibrosis) were explored with multiple logistic regression analysis. We also investigated effect modification of ethnicity on metabolic derangements for NAFLD severity. Within the NASH CRN, 77% (N 5 785) were non-Latino white and 12% (N 5 118) were Latino. Sixty-one percent (N 5 628) had NASH histology and 28% (N 5 291) had advanced fibrosis. Latinos with NASH were younger, performed less physical activity, and had higher carbohydrate intake, compared to non-Latino whites with NASH. Gender, diabetes, hypertension, hypertriglyceridemia, aspartate aminotransferase (AST), platelets, and the homeostasis model assessment of insulin resistance (HOMA-IR) were significantly associated with NASH. Age, gender, AST, alanine aminotransferase, alkaline phosphatase, platelets, total cholesterol, hypertension, and HOMA-IR, but not ethnicity, were significantly associated with advanced fibrosis. The effect of HOMA-IR on the risk of NASH was modified by ethnicity: HOMA-IR was not a significant risk factor for NASH among Latinos (odds ratio [OR] 5 0.93; 95% confidence interval [CI]: 0.85-1.02), but was significant among non-Latino whites (OR, 1.06; 95% CI: 1.01-1.11). Conclusion: Metabolic risk factors and sociodemographic characteristics associated with NASH differ by ethnicity. Additional insights into NASH pathogenesis may come from further studies focused on understanding ethnic differences in this disease. (HEPATOLOGY 2012;55:769-780


πŸ“œ SIMILAR VOLUMES


Racial and ethnic distribution of nonalc
✍ Shiobhan R. Weston; Wendy Leyden; Rose Murphy; Nathan M. Bass; Beth P. Bell; M. πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 188 KB πŸ‘ 1 views

We performed a cross-sectional study of newly diagnosed cases of nonalcoholic fatty liver disease (NAFLD) identified between December 1998 and December 2000 in the Chronic Liver Disease Surveillance Study. We compared the demographic and clinical features of NAFLD in a racially diverse representativ

Nonalcoholic fatty liver disease and liv
✍ Paul Angulo πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 229 KB

Nonalcoholic fatty liver disease affects a substantial proportion of the general population worldwide. This high prevalence of nonalcoholic fatty liver disease has important consequences in the donor selection process for liver transplantation, and in the posttransplant period given the high recurre

Nonalcoholic fatty liver disease after l
✍ Kanthi Yalamanchili; Sherif Saadeh; GΓΆran B. Klintmalm; Linda W. Jennings; Gary πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 262 KB

Nonalcoholic steatohepatitis (NASH) may account for many cases of cryptogenic cirrhosis. If so, then steatosis might recur after liver transplantation. Two thousand fifty-two patients underwent primary liver transplantation for chronic liver disease between 1986 and 2004. Serial liver biopsy samples

Valproate therapy and nonalcoholic fatty
✍ Gerhard J. Luef; Markus Waldmann; Wolfgang Sturm; Anis Naser; Eugen Trinka; Iris πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 77 KB πŸ‘ 1 views

## Abstract Nonalcoholic fatty liver disease was defined recently as another symptom of insulin resistance. Continuous therapy with valproate can result in increased body weight and insulin resistance, but no data are yet available on a possible relationship between valproate and nonalcoholic fatty

Hepatic iron and nonalcoholic fatty live
✍ Zobair M. Younossi; Terry Gramlich; Bruce R. Bacon; Christi A. Matteoni; Navdeep πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 97 KB πŸ‘ 1 views